Navigation Links
Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results
Date:9/14/2009

quarter of 2010 was $496,000 as compared to $231,000 in the comparable quarter of 2009, an increase of 115%. The increase in research and development resulted from the Company's continued efforts to build its Tumorgraft platform and development costs associated with securing the Company's future drug pipeline candidates.

General and Administrative expenses for the first quarter of 2010 was $806,000 as compared to $334,000 in the comparable quarter of 2009, an increase of 141%. The increase is primarily due to the continued investment in our corporate infrastructure to support our overall growth and expansion into Israel and the United Kingdom.

For the first quarter ended July 31, 2009, the Company reported a net loss of $1,003,000 or ($0.03) per share compared to a net loss of $131,000 or $0.00 per share in the comparable quarter in 2009.

The Company's cash and cash equivalents on July 31, 2009 was $1,530,000 compared to $2,745,000 at April 30, 2009.

Doug Burkett, Ph.D., President of Champions Biotechnology, Inc., commented, "this past quarter we saw continued improvement in the Company's revenue growth and we continued to build our Tumorgraft platform." In addition, the Company continued to make progress during the quarter on the following fronts:

  1. The Company saw quarterly top line revenues increase 43% year over year.
  2. Promising discussions with numerous companies for additional service contracts in the Preclinical eValuation business yielded another large new customer early in the second quarter.
  3. The Company advanced its due-diligence and negotiations to in-license promising oncology compounds by leveraging its Tumorgraft platform to select the most promising candidates.
  4. Champions established a collaboration agreement with Do-Coop, an Israel based biotech firm to develop a more soluble form of its SG410 oncology d
    '/>"/>

SOURCE Champions Biotechnology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc.
2. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
3. Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team
4. Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share
5. Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs
6. Champions Biotechnology Reports Fiscal 2008 Full-Year Financial Results
7. Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results
8. Champions Biotechnology, Inc. Establishes UK Subsidiary and Retains General Manager to Expand Its Personalized Oncology Business
9. Champions Biotechnology Partners with Do-Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft(TM) Testing
10. Champions Biotechnology Reports Fiscal 2009 Full-Year Financial Results
11. Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... Texas (PRWEB) , ... July 03, 2015 , ... ... firm, highly-regarded by Fortune 500 companies and professional service industries alike-- typically known ... to make clients laugh, honor a good cause and break from their day ...
(Date:7/3/2015)... 3, 2015 Forskare ... 2015 på  http://www.openinnovationinscience.at till det återkommande ... som hålls i Wien ... med internationella forskare och vetenskapsmän som genomfördes ... två största utmaningar bristen på incitament för ...
(Date:7/3/2015)... , July 3, 2015  Pomerantz LLP announces ... Puma Biotechnology, Inc. ("Puma" or the "Company")(NYSE: PBYI ... filed in United States District Court, Central District of ... is on behalf of a class consisting of all ... 23, 2014 and May 13, 2015 inclusive (the "Class ...
(Date:7/2/2015)... ... 03, 2015 , ... Cuvettes have been used in countless labs for decades. In the ... they needed. As expected, this was a daunting and tiring process looking at endless ... were not able to navigate the complex catalog structure. , Now thanks to FireflySci, scientists ...
Breaking Biology Technology:The Alexander Group Declares Their Independence with a Bit of Levity 2Lansering av världens första program för öppen innovation för att utbilda forskare 2Lansering av världens första program för öppen innovation för att utbilda forskare 3SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 2SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 3SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 4New Cuvette E-Commerce Website Launched by FireflySci 2
... extensive experience in multi-GPU high-performance computing systems ... provide scientists, engineers and researchers with a ... Supercomputer (PSC), which will be shown at ... SC08 Conference, the top international conference for ...
... wine stain birthmarks occur on the face. As such, there is ... reddish-purple skin lesions that can have a huge impact on a patient,s ... use of pulsed dye laser (PDL) therapy and topical Imiquimod to treat ... ...
... , ... San Diego, CA (PRWEB) November 17, 2008 ... company developing solutions based on the products of newborn fibroblasts, today ... conference, taking place November 17-18, 2008 in London. , , ,Dr. ...
Cached Biology Technology:BOXX Personal Supercomputer for Research Scientists Featured at SC08 2Pilot Study Finds Adding Topical Imiquimod To Laser Therapy Improves The Response Of Port Wine Stain Birthmarks 2Pilot Study Finds Adding Topical Imiquimod To Laser Therapy Improves The Response Of Port Wine Stain Birthmarks 3Pilot Study Finds Adding Topical Imiquimod To Laser Therapy Improves The Response Of Port Wine Stain Birthmarks 4Dr. Gail Naughton Speaks on Histogen's Business Plan and the Rise of Bioaesthetic Medicine during Commercial Translation of Regenerative Medicine 2Dr. Gail Naughton Speaks on Histogen's Business Plan and the Rise of Bioaesthetic Medicine during Commercial Translation of Regenerative Medicine 3
(Date:6/24/2015)... YORK , June 24, 2015 This ... market, over the next six years. It contains an ... the industry, along with their impact from the short, ... It also discusses the industry, market, and technology trends ... that the need of concerned authorities to efficiently manage ...
(Date:6/23/2015)... DUBLIN , June 22, 2015 ... has announced the addition of the "Body-Worn ... Share, Growth, Trends and Forecast 2014 - 2020" ... report offers strategic analysis of the global body-worn ... market has been segmented on the basis of ...
(Date:6/17/2015)... GERMANTOWN, Maryland , June 17, 2015 /PRNewswire/ ...   Produktlinie mit DNA-Tests verbessert den Analyseprozess und senkt ... ; Frankfurt Prime Standard: QIA) hat heute in den ... Investigator ® für die ... neuen Kits zur Erstellung genetischer Fingerabdrücke bieten eine integrierte ...
Breaking Biology News(10 mins):Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6
... study led by researchers at the Johns Hopkins ... patients taking the antiretroviral drug efavirenz were more ... to experience virologic failure and death compared to ... prescribed drug for patients undergoing highly active antiretroviral ...
... biologist Ken Catania heard about the peculiar practice of worm ... Panhandle one of his first thoughts was an observation made ... forest, driving a wooden stake into the ground and then ... of steel called a rooping iron. This makes a peculiar ...
... Osteoporosis Day events today in Brussels. This year,s theme ... a global call to take charge and improve osteoporosis ... a disease that can be largely prevented through timely ... run reducing healthcare budgets as well as preventing the ...
Cached Biology News:Efavirenz-based initial therapies associated with better outcomes in HIV-infected adults 2Florida's 'worm grunters' collect bait worms by inadvertently imitating mole sounds 2Florida's 'worm grunters' collect bait worms by inadvertently imitating mole sounds 3Florida's 'worm grunters' collect bait worms by inadvertently imitating mole sounds 4IOF calls on European citizens to stand tall and speak out for their bones 2IOF calls on European citizens to stand tall and speak out for their bones 3
Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
...
... Antigen peptide transporter 2 ... (Peptide transporter PSF2) (Peptide ... (Peptide transporter involved in ... Antigen: ...
... Recognizes Nabeta2. The epitope specific ... in any other known proteins.,SPECIES ... to work on human because ... conserved (17/19 residues). Reactivity with ...
Biology Products: